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The progressive loss in renal function in chronic kidney disease (CKD) results in the 
accumulation of potentially toxic compounds. Early detection of an impaired kidney function 
is primordial towards disease management; hence, there is a clear need for novel 
biomarkers. The objective of this work was to perform a proof-of-concept metabolomics 
discovery study for CKD.  
Serum samples from CKD patients at stage 3 (n=20), at stage 5 on hemodialysis (n=19) and 
from healthy controls (n=20) were monitored on a holistic metabolomics platform combining 
reversed-phase liquid chromatography coupled to high-resolution quadrupole time-of-flight 
mass spectrometry (LC-Q-TOF MS) in both negative and positive ionization mode and gas 
chromatography coupled to quadrupole mass spectrometry (GC-MS). The methodological 
validity was ensured by use of quality control (QC) samples in the analytical setup, and by a 
thorough data analysis strategy for both the GC-MS and the LC-MS part.  
A substantial portion of the serum metabolome was covered. Ninety-one metabolites were 
identified. Forty-nine metabolites were already known in the context of CKD (7 
downregulated and 42 upregulated) while 42 metabolites were yet unknown (11 
downregulated and 31 upregulated). Of the latter, 5 metabolites were found to be 
significantly increased (fold change≥5) at CKD stage 3 compared to control. These 
metabolites were 2-hydroxyhippuric acid glucuronide, 2-/3-hydroxyhippuric acid sulfate, 
hydroxypyridine, methoxy-hydroxyphenylglycol glucuronide and a hexose based 
tetrasaccharide.  
Further targeted analysis in an increased study population will be performed to validate these 
novel, potential biomarkers across all CKD stages. 
